Elicio Therapeutics, Inc.
For the period ended Dec 31, 2024. Filed Mar 31, 2025.
View on SEC.govAbout this filing
A company's yearly report to the SEC, with audited financial statements. It is the fullest account a company gives of its business, its finances and the risks it sees.
FY2024 · Filed Mar 31, 2025
ELTX$1.61-2.1%Stored close · as of Nov 10, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Item 8. Financial Statements and Supplementary Data
The financial statements of Elicio Therapeutics, Inc., listed below are set forth in Item 8 of this Annual Report for the years ended December 31, 2024 and 2023:
INDEX TO CONSOLIDATED FINANCIAL STATEMENTS
| Page | |
|---|---|
| Report of Independent Registered Public Accounting Firm (Baker Tilly US, LLP, Tewksbury, Massachusetts, PCAOB ID: 23) | 102 |
| Consolidated Balance Sheets | 103 |
| Consolidated Statements of Operations and Comprehensive Loss | 104 |
| Consolidated Statements of Convertible Preferred Stock and Stockholders' (Deficit) Equity | 105 |
| Consolidated Statements of Cash Flows | 107 |
| Notes to Consolidated Financial Statements | 109 |
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.